1006377-31-6Relevant articles and documents
Novel Sulfonaminoquinoline Hepcidin Antagonists
-
Page/Page column 141, (2012/09/05)
The present invention relates to novel hepcidin antagonists, pharmaceutical compositions comprising them and the use thereof as medicaments for the use in the treatment of iron metabolism disorders, such as, in particular, iron deficiency diseases and anemias, in particular anemias in connection with chronic inflammatory diseases.
Identification of N-(quinolin-8-yl)benzenesulfonamides as agents capable of down-regulating NFκB activity within two separate high-throughput screens of NFκB activation
Xie, Yuli,Deng, ShiXian,Thomas, Craig J.,Liu, Yidong,Zhang, Ya-Qin,Rinderspacher, Alison,Huang, Wenwei,Gong, Gangli,Wyler, Michael,Cayanis, Efithia,Aulner, Nathalie,Toebben, Udo,Chung, Caty,Pampou, Sergey,Southall, Noel,Vidovic, Dusica,Schuerer, Stephan,Branden, Lars,Davis, R. Eric,Staudt, Louis M.,Inglese, James,Austin, Christopher P.,Landry, Donald W.,Smith, Deborah H.,Auld, Douglas S.
, p. 329 - 335 (2008/09/16)
We describe here a series of N-(quinolin-8-yl)benzenesulfonamides capable of suppressing the NFκB pathway identified from two high-throughput screens run at two centers of the NIH Molecular Libraries Initiative. These small molecules were confirmed in bot
